June 2016 - Cancer Currents Blog
- Prognosis Discussions Improve Understanding of Illness for Patients with Terminal Cancer
Many patients with advanced, incurable cancer have a poor understanding of their prognosis or life expectancy, a new study shows. Patients who discussed their prognosis with their doctors were more likely to understand the serious nature of their illness.
- The Moonshot Blue Ribbon Panel: Moving Toward a Final Report
An update on the activities of the National Cancer Moonshot Initiative’s Blue Ribbon Panel and its work to develop a final report for research ideas to be pursued under this initiative.
- Extended Adjuvant Therapy Beneficial for Some Women with Breast Cancer
Results from a recent clinical trial showed that extending adjuvant therapy with an aromatase inhibitor to 10 years after initial treatment can have important benefits for postmenopausal women with early-stage hormone receptor–positive breast cancer.
- Early-Stage Cancer Trials Support Promise of Precision Medicine, Immunotherapy
Encouraging findings from several early-stage clinical trials featured at the 2016 American Society of Clinical Oncology annual meeting support the promise of precision medicine and immunotherapy.
- Blood Test for Genetic Changes in Tumors Shows Promise as Alternative to Tumor Biopsy
The largest study of its kind to date has shown that a test that assesses DNA mutations and other changes in genetic material shed from tumors into the blood—a liquid biopsy—produced results highly similar to those of traditional tumor biopsies.
- Trials Produce Practice-Changing Results for Brain Cancer
Results from two clinical trials show that treating patients with the chemotherapy drug temozolomide in addition to radiation therapy increased overall and progression-free survival.
- FDA Approves New Immunotherapy Drug for Bladder Cancer
The FDA has approved atezolizumab (Tecentriq®) for the treatment of some patients with urothelial carcinoma, the most common type of bladder cancer.
- Patient-Derived Antibody Appears to Selectively Target Tumor Cells, Spur Immune Attack
The CFH antibodies killed tumor cells in cell lines of several cancer types and slowed tumor growth in mouse models of brain and lung cancer, without evidence of side effects.
- Two New Therapies Approved by FDA for Advanced Kidney Cancer
The FDA has approved two drugs, cabozantinib and lenvatinib, for patients whose advanced kidney cancers have progressed after prior treatment with antiangiogenic therapies.
- Enhanced Risk-Based Lung Cancer Screening May Prevent More Deaths than Current Approaches
A blog post on a modeling study from NCI researchers suggesting that individualized, risk-based selection of ever-smokers for lung cancer screening may prevent more lung cancer deaths compared with current screening recommendations.